Year: 2024

NuVista Energy Ltd. Announces Strong Third Quarter 2024 Financial and Operating Results, LNG Agreement, 2025 Budget, and Enhanced Shareholder Return Strategy

Written by Customer Service on November 8, 2024. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, Nov. 08, 2024 (GLOBE NEWSWIRE) — NuVista Energy Ltd. (“NuVista” or the “Company“) (TSX: NVA) is pleased to announce strong financial and operating results for the three and nine months ended September 30, 2024, and to provide an update on our operational performance. The quality and composition of our asset base consistently enables us to generate strong returns across commodity price cycles. Subsequent to the third quarter, our daily production has reached new record levels, as we continue to invest in new high-return wells and infrastructure projects to support our development plans. We also added LNG market access to our diversified natural gas portfolio and made significant progress on our return of capital to shareholders program through our normal course issuer bid (the “2024 NCIB”),...

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on November 8, 2024. Posted in Public Companies.

Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the end of 2Q 2025 InflaRx pipeline highlighted at multiple medical congresses, including vilobelimab in COVID-19 and hidradenitis suppurativa (HS) and INF904 Phase 2a trial for INF904 expected to initiate by year-end 2024, with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of vilobelimab continues, with discussions ongoing and a CHMP opinion anticipated around mid-November Cash, cash equivalents and marketable securities of €62.0 million, expected to fund operations into 2026JENA, Germany, Nov. 08, 2024 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical...

Form 8.3 – [LEARNING TECHNOLOGIES GROUP PLC – 07 11 2024] – (CGWL)

Written by Customer Service on November 8, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date...

Fortrea Reports Third Quarter 2024 Results

Written by Customer Service on November 8, 2024. Posted in Earnings Releases And Operating Results.

For the three months ended September 30, 2024, from continuing operations:Revenues of $674.9 million GAAP net loss of $(18.5) million Adjusted EBITDA of $64.2 million GAAP and adjusted net income (loss) per diluted share of $(0.21) and $0.23, respectively Book-to-bill ratio of 1.23x, resulting in 1.15x book-to-bill for the trailing 12 monthsDURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today reported financial results for the third quarter ended September 30, 2024. “We had a solid quarter of execution” said Tom Pike, chairman and CEO of Fortrea. “Our book-to-bill ratio for the quarter, as expected, is a nice mix of both large pharma and biotech awards. We have continued to make strong progress in the post-spin separation from our...

Prospect Capital Announces Financial Results for Fiscal September 2024 Quarter

Written by Customer Service on November 8, 2024. Posted in Earnings Releases And Operating Results.

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) — Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended September 30, 2024. “We are rightsizing our common shareholder distribution rate as we continue to execute our long-term income and total return strategy by rotating structured credit CLO equity and real estate investments into our core business of first lien senior secured middle market loans, including sometimes with selected equity co-investments,” said John Barry, Chairman and Chief Executive Officer of Prospect. “Our preferred shareholder cash distributions continue at the contractual rates of such distributions,” said Mr. Barry. “CLO equity and real estate investments have generated solid unlevered investment-level gross...

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

Written by Customer Service on November 8, 2024. Posted in Public Companies.

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced eight presentations spanning its innovative portfolio of late-stage products and product candidates in psychiatry and neurology at NEI Congress 2024, being held Nov. 7 – Nov. 10, 2024, in Colorado Springs, Colorado. Details for the presentations are as follows: Major Depressive Disorder Title: AXS-05 (Auvelity®) in Major Depressive Disorder: Pooled Data from Two Six-Week Controlled Trials (GEMINI and ASCEND)Presentation Date and Time: Friday, Nov. 8, 3:35 – 4:30 p.m. ETLead Author: Craig Chepke, MD, SUNY Upstate Medical UniversityPoster Number: 101 Title: Effects of AXS-05 (Auvelity®) in Improving...

Onex Reports Third Quarter 2024 Results

Written by Customer Service on November 8, 2024. Posted in Public Companies.

All amounts in U.S. dollars unless otherwise stated Launches substantial issuer bid for up to C$400 million of its Subordinated Voting Shares TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the third quarter and nine months ended September 30, 2024. In a separate news release issued today, Onex also announced that it has commenced a Substantial Issuer Bid. “We are advancing our strategic plan focused on value creation, accelerating profitability and the long-term compounding of our investing capital,” said Bobby Le Blanc, CEO and President. “The third quarter was marked by continued growth in investing capital per share and successful investing and realization activity across our platforms. The launch of a substantial issuer bid reflects our confidence in the inherent...

Seer to Participate in Upcoming November Investor Conferences

Written by Customer Service on November 8, 2024. Posted in Public Companies.

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences:Guggenheim Inaugural Healthcare Innovation Conference in Boston, MAFireside chat on Monday, November 11th at 11:30 a.m. Eastern Time Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NYFireside chat on Thursday, November 21st at 10:00 a.m. Eastern TimeLive webcasts of the sessions will be available on the Investor section of Seer’s website at investor.seer.bio. Archived replays will be available on the company’s website following the conference. About SeerSeer is a life sciences company developing transformative products that open...

Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

Written by Customer Service on November 8, 2024. Posted in Public Companies.

HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately...

Velocity One Signs Merger Agreement with EMCORE (EMKR)

Written by Customer Service on November 8, 2024. Posted in Mergers And Acquisitions.

Transaction will unite industry leaders to create an emerging force in the aerospace and defense industry FAIRFIELD, New Jersey, Nov. 08, 2024 (GLOBE NEWSWIRE) — Velocity One, a newly formed aerospace manufacturing holding company, announced today it has signed a merger agreement with EMCORE Corporation (Nasdaq: EMKR) (“EMCORE”), a provider of inertial navigation solutions to the aerospace and defense industry. Under the agreement, EMCORE will become a wholly owned subsidiary of Velocity One. The purchase price of $3.10 per share in cash, backed by Charlesbank Capital Partners (“Charlesbank”), a private investment firm with more than $22 billion of total assets*, has been unanimously approved by the EMCORE board of directors. Velocity One will now have three industry leaders operating under its wing. In addition to EMCORE, it will...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals